Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
IMNM
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
zacks.com
11 hours ago
businesswire.com
16 hours ago
fool.com
17 hours ago
businesswire.com
17 hours ago
zacks.com
18 hours ago
seekingalpha.com
22 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.36
vs -0.75
Q4.23
N/A
-0.54
vs -0.64
Q1.24
N/A
-0.34
vs -0.35
Q2.24
N/A
-0.49
vs -0.46
Q3.24
N/A
-0.78
vs -0.36
Q4.24
N/A
-0.84
vs -0.54
Q1.25
N/A
-0.52
vs -0.34
Q2.25
N/A
-0.50
vs -0.49
Q3.25
N/A
-0.55
vs -0.78
Q4.25
N/A
-0.59
vs -0.84
Sales Growth
YoY
Current
Estimates
Q3.23
NA
3.6M vs NA
Q4.23
NA
3.8M vs NA
Q1.24
-56%
1M vs 2.4M
Q2.24
-45%
2.4M vs 4.3M
Q3.24
-18%
2.9M vs 3.6M
Q4.24
-28%
2.7M vs 3.8M
Q1.25
+184%
2.9M vs 1M
Q2.25
+70%
4M vs 2.4M
Q3.25
-95%
142.9K vs 2.9M
Q4.25
-89%
300K vs 2.7M
Return on Equity
QoQ
Q1.23
-29%
-0.29
vs -0.50
Q2.23
-60%
-0.60
vs -0.29
Q3.23
-72%
-0.72
vs -0.60
Q4.23
-77%
-0.77
vs -0.72
Q1.24
-45%
-0.45
vs -0.77
Q2.24
-14%
-0.14
vs -0.45
Q3.24
-22%
-0.22
vs -0.14
Q4.24
-44%
-0.44
vs -0.22
Q1.25
-14%
-0.14
vs -0.44
Q2.25
-16%
-0.16
vs -0.14
Institutionnal Ownership
QoQ
Q1.23
33
33
vs 28
18%
Q2.23
41
41
vs 33
24%
Q3.23
39
39
vs 41
-5%
Q4.23
60
60
vs 39
54%
Q1.24
108
108
vs 60
80%
Q2.24
116
116
vs 108
7%
Q3.24
122
122
vs 116
5%
Q4.24
124
124
vs 122
2%
Q1.25
147
147
vs 124
19%
Q2.25
148
148
vs 147
1%
Forecast
285%2026-Revenue
-374%2026-EPS
107%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Piper Sandler
initialisePrevious: Not converted
2024-05-31
Now: Overweight
Guggenheim
initialisePrevious: Not converted
2024-04-15
Now: Buy
Quote Panel
Key Metrics
Relative Strength
IMNM
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.03 ( -0.29%)
Relative Strenght
71
Volume Buzz
-47%
Earning Acce
Yes
Dist 52w H.
39%